Antibody gene therapy for treatment and prevention of infection by rabies lyssavirus
AssigneeAuburn University
InventorsHenry J. BAKER, Douglas R. MARTIN, Miguel SENA-ESTEVES, Kent R. VAN KAMPEN
Life of this patent
Estimating the term…
Loading patent…
AssigneeAuburn University
InventorsHenry J. BAKER, Douglas R. MARTIN, Miguel SENA-ESTEVES, Kent R. VAN KAMPEN
Estimating the term…
Disclosed are compositions, vectors, and methods for treating and preventing rabies lyssavirus infection in a subject in need thereof, including rabies lyssavirus encephalitis. The disclosed compositions relate to anti-rabies immunoglobulins and vectors for expressing anti-rabies immunoglobulins such as adeno-associated virus (AAV) vectors that express anti-rabies immunoglobulins in a subject in need thereof. In some embodiments, the disclosed methods relate to treating and/or preventing an infection by rabies lyssavirus in a subject in need thereof, the methods comprising administering to the subject a dose of an adeno-associated virus (AAV) vector that expresses an immunoglobulin that binds and neutralizes rabies lyssavirus in the subject.
-29. (canceled)
A method for treating and/or preventing an infection by rabies lyssavirus in a subject in need thereof, the method comprising administering to the subject a dose of an adeno-associated virus (AAV) vector, wherein the AAV vector encodes SEQ ID NO:
An adeno-associated virus (AAV) vector that expresses in the central nervous system (CNS) of a subject an immunoglobulin that binds Glycoprotein G of rabies lyssavirus and has neutralizing activity to rabies lyssavirus in host cells exposed to rabies lyssavirus compared to host cells in a subject not administered the AAV vector, wherein the AAV vector is effective for expressing SEQ ID NO:1 connected to the CR57 rabies variable heavy chain region and variable light chain region.
Dependencies are inferred from the claim text.